Cerevel Therapeutics Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $23.35
- Today's High:
- $23.975
- Open Price:
- $23.93
- 52W Low:
- $22.1
- 52W High:
- $41.46
- Prev. Close:
- $24.04
- Volume:
- 590832
Company Statistics
- Market Cap.:
- $5.24 billion
- Book Value:
- 2.754
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.87%
- Return on Equity TTM:
- -81.31%
Company Profile
Cerevel Therapeutics Holdings Inc had its IPO on 2020-10-28 under the ticker symbol CERE.
The company operates in the Healthcare sector and Biotechnology industry. Cerevel Therapeutics Holdings Inc has a staff strength of 319 employees.
Stock update
Shares of Cerevel Therapeutics Holdings Inc opened at $23.93 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $23.35 - $23.98, and closed at $23.45.
This is a -2.45% slip from the previous day's closing price.
A total volume of 590,832 shares were traded at the close of the day’s session.
In the last one week, shares of Cerevel Therapeutics Holdings Inc have slipped by -0.89%.
Cerevel Therapeutics Holdings Inc's Key Ratios
Cerevel Therapeutics Holdings Inc has a market cap of $5.24 billion, indicating a price to book ratio of 6.9642 and a price to sales ratio of 0.
In the last 12-months Cerevel Therapeutics Holdings Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-389763008. The EBITDA ratio measures Cerevel Therapeutics Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cerevel Therapeutics Holdings Inc’s operating margin was 0% while its return on assets stood at -31.87% with a return of equity of -81.31%.
In Q1, Cerevel Therapeutics Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cerevel Therapeutics Holdings Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.6 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cerevel Therapeutics Holdings Inc’s profitability.
Cerevel Therapeutics Holdings Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -11.6845. Its price to sales ratio in the trailing 12-months stood at 0.
Cerevel Therapeutics Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $930.35 million
- Total Liabilities
- $62.96 million
- Operating Cash Flow
- $110.78 million
- Capital Expenditure
- $336000
- Dividend Payout Ratio
- 0%
Cerevel Therapeutics Holdings Inc ended 2024 with $930.35 million in total assets and $0 in total liabilities. Its intangible assets were valued at $930.35 million while shareholder equity stood at $431.71 million.
Cerevel Therapeutics Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $62.96 million in other current liabilities, 16000.00 in common stock, $-1072041000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $153.82 million and cash and short-term investments were $826.99 million. The company’s total short-term debt was $3,028,000 while long-term debt stood at $335.96 million.
Cerevel Therapeutics Holdings Inc’s total current assets stands at $840.78 million while long-term investments were $36.05 million and short-term investments were $673.17 million. Its net receivables were $3.20 million compared to accounts payable of $7.32 million and inventory worth $0.
In 2024, Cerevel Therapeutics Holdings Inc's operating cash flow was $110.78 million while its capital expenditure stood at $336000.
Comparatively, Cerevel Therapeutics Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $23.45
- 52-Week High
- $41.46
- 52-Week Low
- $22.1
- Analyst Target Price
- $36.44
Cerevel Therapeutics Holdings Inc stock is currently trading at $23.45 per share. It touched a 52-week high of $41.46 and a 52-week low of $41.46. Analysts tracking the stock have a 12-month average target price of $36.44.
Its 50-day moving average was $25.96 and 200-day moving average was $28.84 The short ratio stood at 7.02 indicating a short percent outstanding of 0%.
Around 1755.7% of the company’s stock are held by insiders while 8881.3% are held by institutions.
Frequently Asked Questions About Cerevel Therapeutics Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company’s products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson’s disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.